A phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma

Anna C. Ferrari, Abraham Chachoua, Harvinder Singh, Mark Rosenthal, Samir Taneja, Myron Bednar, John Mandeli, Franco Muggia

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'A phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma'. Together they form a unique fingerprint.

Medicine and Dentistry

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science